Cargando…
miR-331-3p and Aurora Kinase inhibitor II co-treatment suppresses prostate cancer tumorigenesis and progression
RNA-based therapeutics could represent a new avenue of cancer treatment. miRNA 331-3p (miR-331-3p) is implicated in prostate cancer (PCa) as a putative tumor suppressor, but its functional activity and synergy with other anti-tumor agents is largely unknown. We found miR-331-3p expression in PCa tum...
Autores principales: | Epis, Michael R., Giles, Keith M., Beveridge, Dianne J., Richardson, Kirsty L., Candy, Patrick A., Stuart, Lisa M., Bentel, Jacqueline, Cohen, Ronald J., Leedman, Peter J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5589646/ https://www.ncbi.nlm.nih.gov/pubmed/28903407 http://dx.doi.org/10.18632/oncotarget.18664 |
Ejemplares similares
-
miR-331-3p regulates expression of neuropilin-2 in glioblastoma
por: Epis, Michael R., et al.
Publicado: (2013) -
The tumor suppressor miR-642a-5p targets Wilms Tumor 1 gene and cell-cycle progression in prostate cancer
por: Beveridge, Dianne J., et al.
Publicado: (2021) -
Phosphorylation at serine 331 is required for Aurora B activation
por: Petsalaki, Eleni, et al.
Publicado: (2011) -
Regulation of Epidermal Growth Factor Receptor Signaling and Erlotinib Sensitivity in Head and Neck Cancer Cells by miR-7
por: Kalinowski, Felicity C., et al.
Publicado: (2012) -
microRNA-7-5p inhibits melanoma cell proliferation and metastasis by suppressing RelA/NF-κB
por: Giles, Keith M., et al.
Publicado: (2016)